PEGASYS + Aspirin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Polycythemia Vera
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Trial Timeline
Sep 1, 2011 → Dec 1, 2016
NCT ID
NCT01259817About PEGASYS + Aspirin
PEGASYS + Aspirin is a phase 2 stage product being developed by Roche for High Risk Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT01259817. Target conditions include High Risk Polycythemia Vera, High Risk Essential Thrombocythemia.
What happened to similar drugs?
6 of 20 similar drugs in High Risk Polycythemia Vera were approved
Approved (6) Terminated (7) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01259817 | Phase 2 | Completed |
Competing Products
20 competing products in High Risk Polycythemia Vera